According to the Marshall Pathogenesis, patients must generate immunopathology in order to recover from chronic inflammatory disease. To this end, regular dosing of olmesartan (Benicar) is critical. Olmesartan's action as a VDR agonist allows Marshall Protocol patients to activate their innate immune response. This is evident in patients taking MP antibiotics who do not begin killing bacteria until they take olmesartan.